12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cangrelor: Phase III data

The double-blind, U.S. Phase III CHAMPION PHOENIX trial in 10,900 patients undergoing PCI showed that IV cangrelor followed by Plavix clopidogrel after discontinuation of cangrelor met the primary composite endpoint of reducing all-cause mortality, MI, ischemia-driven revascularization and stent thrombosis at 48 hours vs. placebo plus Plavix. The Medicines Co. plans to submit the CHAMPION PHOENIX data along with data from the Phase II BRIDGE trial in an NDA to FDA and an MAA...

Read the full 358 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >